World Health Organization Raises Alert Over Acute Lack of Weight-Loss Jabs
Under 10% of individuals that would benefit from weight-loss injections like Wegovy are able to get them, caution the WHO as it publishes its first guidance on the drugs.
Considering more than one billion people worldwide currently living with obesity, it is urging broader and more equitable availability to these injectable treatments.
Per estimates, in excess of 2,000,000,000 will be living with obesity by 2030 unless action is taken.
"The new guidance recognises that excess weight is a lifelong illness that can be managed with thorough and continuous treatment," remarked its chief Tedros Adhanom Ghebreyesus.
Significant expense, limited production capacity, and logistical bottlenecks are key hurdles to universal availability to the jabs that can aid individuals in losing substantial weight, notes the agency.
Weight-Loss Drug Supply Crisis
Even under the present most favorable scenario, the production of such drugs could only cover around 100 million people – under 10% of the global need, according to the WHO.
The guideline urges governments and firms to increase availability, through strategies like licensing agreements.
The intellectual property rights on semaglutide – the core ingredient of a leading brand – is due to expire in several countries in 2026.
The Way Obesity Jabs Function
The injections imitate a body's own hormone to reduce digestion speed, curb appetite and enhance feelings of fullness so users consume fewer calories.
Individuals usually begin shedding pounds within a few weeks of commencing the regular doses.
Studies indicates users may see weight return within a year of discontinuing the treatment, when their normal hunger come back.
Being above a healthy weight raises your chance for contracting diseases, like type 2 diabetes, cardiovascular issues, brain attack, and certain cancers.
Excess weight concerns individuals in all nations and was linked to millions of deaths worldwide in 2024, according to the health agency.
